Solid Biosciences Inc. (SLDB)
- Previous Close
9.04 - Open
9.06 - Bid 9.21 x 100
- Ask 9.32 x 100
- Day's Range
8.95 - 9.61 - 52 Week Range
1.81 - 15.05 - Volume
180,646 - Avg. Volume
262,103 - Market Cap (intraday)
349.063M - Beta (5Y Monthly) 1.94
- PE Ratio (TTM)
-- - EPS (TTM)
-4.83 - Earnings Date May 9, 2024 - May 13, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
17.00
Solid Biosciences Inc., a life science company, develops therapies for neuromuscular and cardiac diseases in the United States. The company's lead product candidate is SGT-003, a gene transfer candidate for the treatment of Duchenne muscular dystrophy; and SGT-501 to treat Catecholaminergic polymorphic ventricular tachycardia. It is also developing AVB-401 for the treatment of BAG3-mediated dilated cardiomyopathy; SGT-601 to treat a rare cardiac disease characterized by mutations in the gene that codes for cardiac troponin T protein, which helps coordinate contraction of the heart muscle; SGT-701 for treatment of rare inherited disease characterized by mutations in the RBM20 gene, a cardiac splicing factor that regulates alternative splicing, and codes for RNA binding motif protein 20; and AVB-202-TT to treat Friedreich's ataxia, as well as other drugs for the treatment of cardiac and other diseases. In addition, the company is involved in developing platform technologies, including capsid libraries and dual gene expression, a technology for packaging multiple transgenes into one capsid. The company has collaboration and license agreement with Ultragenyx Pharmaceutical Inc. to develop and commercialize new gene therapies for Duchenne; and a license agreement with the University of Washington, University of Missouri, and University of Florida. Solid Biosciences Inc. was incorporated in 2013 and is headquartered in Charlestown, Massachusetts.
www.solidbio.comRecent News: SLDB
Performance Overview: SLDB
Trailing total returns as of 4/23/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: SLDB
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: SLDB
Valuation Measures
Market Cap
341.32M
Enterprise Value
243.95M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
2.70
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
-2.40
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-30.67%
Return on Equity (ttm)
-56.79%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-96.02M
Diluted EPS (ttm)
-4.83
Balance Sheet and Cash Flow
Total Cash (mrq)
123.64M
Total Debt/Equity (mrq)
20.77%
Levered Free Cash Flow (ttm)
-64.43M